<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100904">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02006459</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2012-123</org_study_id>
    <nct_id>NCT02006459</nct_id>
  </id_info>
  <brief_title>Involvement of Extrapancreatic Factors on Gastrointestinal-mediated Glucose Disposal</brief_title>
  <acronym>Px-GIGD</acronym>
  <official_title>Involvement of Extrapancreatic Factors on Gastrointestinal-mediated Glucose Disposal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Foundation for the Study of Diabetes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We want to investigate the mechanisms of extrapancreatic effects on
      gastrointestinal-mediated glucose disposal. In order to do so we will perform oral glucose
      tolerance tests and isoglycemic intravenous glucose infusions in total pancreatectomised
      patients and in healthy controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the current project we wish to identify the possible contribution of extrapancreatic
      effects on gastrointestinal-mediated glucose disposal (GIGD). GIGD reflects the percentage
      of an individual's glucose disposal following oral glucose tolerance test (OGTT) which is
      caused by the oral route of glucose administration. In healthy subjects GIGD amounts to
      ~60%. GIGD describes not only the impact of the incretin effect (insulinotropic substances
      released upon intestinal stimulation) but includes all factors affecting glucose disposal
      differently during oral vs. iv administration of glucose (including neural reflexes,
      activation of afferent nerves in the intestinal mucosa, differences in glucagon secretion,
      hepatic glucose production and first-pass hepatic uptake of glucose, differences in portal
      and venous blood glucose concentrations and/or at the present unknown factors. It is likely
      that the incretin effect (pancreatic effect) constitutes a major contributor to GIGD, but so
      far it has been impossible to discriminate between pancreatic and extrapancreatic mechanisms
      underlying GIGD
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Gastrointestinal-mediated glucose disposal (GIGD)</measure>
    <time_frame>Calculated when the study days are all complete. approximately in 6month</time_frame>
    <safety_issue>No</safety_issue>
    <description>GIGD will be calculated based on the amounts of glucose utilised during the two glucose administrations forms, OGTT and IIGI (GIGD (%) = 100%×(glucoseOGTT-glucoseIIGI)/glucoseOGTT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>endogenous glucose production</measure>
    <time_frame>Endogenous glucose production will be calculated based on blood samples at time points: -30,-15,0,10,20,30,50,70,90,120,150,180 min on all days.</time_frame>
    <safety_issue>No</safety_issue>
    <description>calculated based on infusions of stable isotope marked glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incretin Hormones</measure>
    <time_frame>incretin hormone levels will be measured at time points: -30,-15,0,10,20,30,50,70,90,120,150,180 min on all days.</time_frame>
    <safety_issue>No</safety_issue>
    <description>GIP, GLP-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma Glucagon</measure>
    <time_frame>Glucagon will be measured at time points: -30,-15,0,10,20,30,50,70,90,120,150,180 min on all days.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety, hunger, appetite</measure>
    <time_frame>Satiety, hunger and appetite will be measured at time points:0,30,60,90,120,150,180 min during each day.</time_frame>
    <safety_issue>No</safety_issue>
    <description>Will be measured with visual analogue scales (VAS)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Diabetes</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum and buffycoat
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients operated at/or cared for at the endocrinology out-patient-clinic,
        Rigshospitalet, University of Copenhagen, Copenhagen Denmark
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pancreatectomized patients

               -  Caucasians above 18 years of age who have undergone total pancreatectomy

               -  Normal haemoglobin

               -  Informed consent Healthy Subjects

               -  Normal fasting plasma glucose (FPG) and normal HbA1C (according to the World
                  Health Organization (WHO) criteria)

               -  Normal haemoglobin

               -  Age above 18 years

               -  Informed consent

        Exclusion Criteria:

          -  Pancreatectomized patients

               -  Inflammatory bowel disease

               -  Operation within the last 3 months

               -  Ongoing chemotherapy or chemotherapy within the last 3 months

               -  Ostomy

               -  Nephropathy (serum creatinine &gt;150 µM and/or albuminuria)

               -  Severe liver disease (serum alanine aminotransferase (ALAT) and/or serum
                  aspartate aminotransferase (ASAT) &gt;3×normal values)

               -  Pregnancy and/or breastfeeding

               -  Age above 80 years

               -  Any condition that the investigator feels would interfere with trial
                  participation Healthy Subjects

               -  Diabetes mellitus (DM)

               -  Prediabetes (impaired glucose tolerance and/or impaired FPG)

               -  First degree relatives with DM

               -  Inflammatory bowel disease

               -  Intestinal resection and/or ostomy

               -  Nephropathy (serum creatinine &gt;150 µM and/or albuminuria

               -  Liver disease (ALAT and/or serum ASAT &gt;2×normal values)

               -  Pregnancy and/or breastfeeding

               -  Age above 80 years

               -  Any condition that the investigator feels would interfere with trial
                  participation
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Asger Lund, MD</last_name>
    <phone>+45 39772689</phone>
    <email>lund.asger@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Filip Krag Knop, MD, PhD</last_name>
    <phone>+45 39772689</phone>
    <email>filipknop@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diabetes Research Division, University Hospital Gentofte</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Asger Lund, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>December 4, 2013</lastchanged_date>
  <firstreceived_date>November 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Asger Lund</investigator_full_name>
    <investigator_title>MD, PhD-student</investigator_title>
  </responsible_party>
  <keyword>Gastrointestinal-mediated glucose disposal</keyword>
  <keyword>Total pancreatectomy</keyword>
  <keyword>Incretin hormones</keyword>
  <keyword>Glucagon</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
